COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00377195
Recruitment Status : Unknown
Verified February 2018 by Trans Tasman Radiation Oncology Group.
Recruitment status was:  Active, not recruiting
First Posted : September 18, 2006
Last Update Posted : February 28, 2018
Australasian Leukaemia and Lymphoma Group
Peter MacCallum Cancer Centre, Australia
Information provided by (Responsible Party):
Trans Tasman Radiation Oncology Group

Brief Summary:

This prospective study will test the following hypotheses in patients with stage I-II low grade marginal zone (MZ) lymphoma:

  • Involved Field Radiotherapy will produce a complete response rate of > 90%
  • Radiotherapy will be associated with a locoregional progression of < 20% after 10 years
  • Death from MZ lymphoma will occur in < 40% of patients within 10 years of radiotherapy

This study secondary objectives are:

  • To collect information on the prevalence of H. pylori in non-gastric MALT lymphoma
  • To estimate rates of acute and late toxicity of radiotherapy

Condition or disease Intervention/treatment Phase
Non-gastric Marginal Zone Lymphoma Radiation: Involved Field Radiotherapy Phase 2

Detailed Description:

Aims of the study :

  • To conduct the first multicentre prospective trial of radiotherapy (RT) in stage I-II Marginal Zone Lymphoma (MZL)
  • To prospectively identify causal factors for MZL, including infection and inflammatory disease

This study will be the first large trial of any form of therapy for stage I-II, non-gastric marginal zone lymphoma. There is an enormous deficit in the literature with respect to this fascinating but relatively recently-recognised entity. MZL is commonly associated with underlying inflammatory or infective disorders and it is clear, at least in some cases with infection by organisms called Helicobacter pylori and Chlamydia psitacci, that the inflammatory condition can actually cause the lymphoma. The role of H. pylori infection has not been well studied in non gastric MZL in large prospective studies, despite anecdotal reports of regression of non gastric MZL after H. pylori eradication. There have been reports of responses to doxycycline (antibacterial) therapy in patients with evidence of chlamydial infection (C. psitacci) in MZL of the tissues around the eye. This association has not been well studied in any large prospective study and no long-term data for doxycycline therapy exist. Management of stage I-II MZL is variable and often ad-hoc in Australia, despite significant retrospective evidence to support radiotherapy (RT) as the curative treatment modality of choice. In this TROG/ALLG joint study, 100 patients will be recruited over 5 years. All patients will undergo breath tests or endoscopy to detect H. pylori infection. Ocular MZL specimens will be sent to Italy to test for C. psitacci. Patients will receive highly standardised treatment with RT. This study will definitively document the efficacy and safety of RT in stage I and II non-gastric MZL and will include patients with stage IV disease limited to paired-organs, as this disease shows a tendency to home in exclusively on particular organs, such as salivary glands.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Single Arm Trial of Involved Field Radiotherapy Alone for Stage I-II Low Grade Non-gastric Marginal Zone Lymphoma
Actual Study Start Date : July 8, 2007
Actual Primary Completion Date : April 24, 2017
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: 1 Radiation: Involved Field Radiotherapy

The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.

Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days.

Other Name: Radiation

Primary Outcome Measures :
  1. Freedom from locoregional progression (FFLRP) rate [ Time Frame: There will be an interim analysis at the end of accual (approx 5 years), at 5 years from the end of accrual and a final analysis at 10 years form the end of accrual. ]
  2. Complete response rate [ Time Frame: A final analysis at 10 years form the end of accrual. ]
  3. Cancer-specific survival [ Time Frame: A final analysis at 10 years form the end of accrual. ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: A final analysis at 10 years form the end of accrual. ]
  2. Progression free survival [ Time Frame: A final analysis at 10 years form the end of accrual. ]
  3. Freedom from progression [ Time Frame: A final analysis at 10 years form the end of accrual. ]
  4. Acute and Late Toxicity rates [ Time Frame: There will be an interim analysis at the end of accual (approx 5 years), at 5 years from the end of accrual and a final analysis at 10 years form the end of accrual. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of at least 18 years old with histologically documented non-gastric marginal zone lymphoma.
  • Disease limited to stages I and II after adequate staging (see Appendix II), patients with stage IV with extranodal disease confined to paired organs (e.g. salivary glands) and including any local extension of this disease into adjacent tissues. Patients with involved lymph nodes on the same side of the diaphragm in addition to paired organ involvement are also eligible, provided all involved tumour sites, nodal and extranodal, can be irradiated to 30 Gy within the tolerance of the relevant normal tissues. If paired organ involvement was regarded as a single extranodal site (rather than 2 separate sites and hence stage IV), eligible patients would then be regarded as having stage IE or IIE disease. Patients with wider dissemination (bone marrow, liver etc) are ineligible.
  • Anticipated life expectancy > 2 years
  • Given written informed consent
  • Been assessed by a radiation oncologist
  • Agree to undergo breath testing for H. pylori and/or oesophagogastroduodenoscopy to exclude active infection with helicobacter pylori
  • Must be available for long-term follow up

Exclusion Criteria:

  • Splenic marginal zone lymphoma
  • Received previous locoregional radiotherapy
  • A medical contraindication to radiotherapy
  • Any previous or concurrent malignancy other than curatively treated non-melanoma skin cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and treatment-free for 5 years
  • Such extensive involvement of the thorax that treatment with radiotherapy alone would be hazardous because of excessive lung irradiation, even if a shrinking field technique were employed
  • Suspected or confirmed pregnancy
  • Transformation to large cell lymphoma or other aggressive histology
  • Disease that is widely disseminated (bone marrow, liver etc)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00377195

Layout table for location information
Australia, New South Wales
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Calvary Mater Newcastle
Newcastle, New South Wales, Australia
Australia, Queensland
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Australia, Victoria
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Sponsors and Collaborators
Trans Tasman Radiation Oncology Group
Australasian Leukaemia and Lymphoma Group
Peter MacCallum Cancer Centre, Australia
Layout table for investigator information
Study Chair: Michael MacManus Peter MacCallum Cancer Centre, Australia
Additional Information:
Layout table for additonal information
Responsible Party: Trans Tasman Radiation Oncology Group Identifier: NCT00377195    
Other Study ID Numbers: TROG 05.02
First Posted: September 18, 2006    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Keywords provided by Trans Tasman Radiation Oncology Group:
Marginal Zone Lymphoma
Involved field radiotherapy
H. pylori
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin